- Benzylamine derivatives and its application on the medicament
-
The invention provides novel benzylamine derivatives or stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or pro-drugs thereof for treating Alzheimer diseases. The invention also provides a medicine composition containing a compound provided by the invention and a method for treating the Alzheimer diseases by using the compound or the medicine composition of the compound provided by the invention.
- -
-
Paragraph 0164; 0170; 0171
(2017/08/25)
-
- Substituted heterocyclic compound and its application on the medicament
-
The invention provides a novel substituted heterocyclic compound or stereisomers, stereomers, tautomers, oxynitrides, hydrates, solvates, metabolites, and pharmaceutically acceptable salts or prodrugs thereof. The novel substituted heterocyclic compound i
- -
-
Paragraph 0209; 0210; 0211; 0212
(2016/10/09)
-
- TETRACYCLIC AUTOTAXIN INHIBITORS
-
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
- -
-
Paragraph 00396
(2015/06/08)
-
- Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)
-
Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC50 = 4 nM, Eff = 149%). Oral administration of 6m to LDLR-/- mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.
- Flatt, Brenton,Martin, Richard,Wang, Tie-Lin,Mahaney, Paige,Murphy, Brett,Gu, Xiao-Hui,Foster, Paul,Li, Jiali,Pircher, Parinaz,Petrowski, Mary,Schulman, Ira,Westin, Stefan,Wrobel, Jay,Yan, Grace,Bischoff, Eric,Daige, Chris,Mohan, Raju
-
supporting information; experimental part
p. 904 - 907
(2009/12/24)
-
- AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS
-
The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
- -
-
Page/Page column 110; 111; 117
(2008/06/13)
-
- NOVEL TRICYCLIC HETEROCYCLE COMPOUND
-
―The present invention relates to the compound represented by formula (I) ????????A―X―Y―Z―B?????(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.
- -
-
Page/Page column 58
(2008/06/13)
-
- -3 (SULFONAMIDOETHYL) -INDOLE DERIVATIES FOR USE AS GLUCOCORTICOID MIMETICS IN THE TREATMENT OF INFLAMMATORY, ALLERGIC AND PROLIFERATIVE DISEASES
-
Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, and Y are as defined herein, or a tautomer, prodrug, solvate, or sal
- -
-
Page/Page column 66
(2010/02/06)
-
